Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.74 |
| ▸ | MAOA | P21397 | 5/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 8/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7533561 | 0.86 | NPC1 (0.74) | MAOBMAOANPC1RAB9ALMNA | |
| SCHEMBL18595541 | 0.86 | NPC1 (0.61) | MAOBMAOANPC1RAB9ALMNA | |
| SCHEMBL29429724 | 0.85 | MAOB (1.00) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5818325 | 0.85 | NPC1 (0.75) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL19476163 | 0.83 | NPC1 (0.78) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL28082015 | 0.82 | MAOA (0.59) | MAOBMAOANPC1RAB9ALMNA | |
| SCHEMBL12764054 | 0.81 | EGFR (0.74) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL13564494 | 0.81 | NPC1 (0.62) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL27337170 | 0.81 | NPC1 (0.73) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL17206335 | 0.81 | NPC1 (0.69) | NPC1RAB9ALMNASMN1; SMN2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287291-B2 | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180051031-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | THE SCRIPPS RESEARCH INSTITUTE | 2018-02-22 | — | — | US | disclosed |
| US-9586974-B2 | Cyclic N-acyl O-amino phenol CBI derivative | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160016972-A1 | Cyclic N-Acyl O-Amino Phenol CBI Derivative | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
| WO-2014160586-A1 | CYCLIC N-ACYL O-AMINO PHENOL CBI DERIVATIVE | THE SCRIPPS RESEARCH LINSTITUTE (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2009064913-A1 | CHIMER CONTAINING A TARGETING PORTION LINKED TO A SCISSION-ACTIVATED DUOCARMYCIN-TYPE PRODRUG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-22 | — | — | WO | disclosed |
| US-7235578-B2 | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VDR, CYP2R1, CYP24A1 | MAOB 2836/4885MAOA 3752/4885NPC1 1188/4885 |
| US-20160016972-A1 | Cyclic N-Acyl O-Amino Phenol CBI Derivative | CCNI, DBI, SUB1 | MAOB 129/4885MAOA 195/4885NPC1 2376/4885 |
| US-20180051031-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | CD22, GDI2, GDI1 | MAOB 1677/4885MAOA 1601/4885NPC1 2298/4885 |
| US-10287291-B2 | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use | CD22, GDI2, GDI1 | MAOB 1677/4885MAOA 1601/4885NPC1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.